Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Steven G. DuBois, Araz Marachelian, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Susan G. Groshen, Jemily Malvar, Rochelle Bagatell, Lars M. Wagner, John M. Maris, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Denice D Tsao-Wei, Katherine K. Matthay, Yael P. Mosse
Institutions: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Children's Hospital of Los Angeles, Mayo Clinic, University of Southern California, USC Norris Comprehensive Cancer Center, Children's Hospital of Philadelphia, University of Kentucky, Markey Cancer Center, University of California, San Francisco
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2892090660